{"product_id":"international-myeloma-society-educational-workshop-2025","title":"International Myeloma Society Educational Workshop 2025","description":"\u003cul\u003e\n  \u003cli\u003eInclude:  videos + file sub vtt +  pdf, size:  GB\u003c\/li\u003e\n  \u003cli\u003eTarget Audience: hematologists, medical oncologists, nephrologists, and infectious disease specialists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis dynamic educational workshop focuses on the diagnosis, treatment, and monitoring of plasma cell malignancies, exploring both current practices and opportunities for improvement. The program features a blend of lectures and interactive roundtable discussions centered on hot and controversial topics. It highlights point-counterpoint conversations between invited speakers and local hematologists, utilizing challenging clinical cases and questions to drive the educational experience in the evolving landscape of multiple myeloma.\u003c\/p\u003e\n\u003cp\u003eLearning Objectives\u003c\/p\u003e\n\u003ch3\u003eUpon completion of this workshop, participants will be able to:\u003c\/h3\u003e\n\u003cp\u003eEvaluate current diagnostic testing, minimal residual disease (MRD) testing, and new risk stratification models for multiple myeloma.\u003c\/p\u003e\n\u003cp\u003eDetermine optimal management strategies for Smoldering Multiple Myeloma (SMM) and Newly Diagnosed Multiple Myeloma (NDMM), differentiating between transplant-eligible and non-eligible patients.\u003c\/p\u003e\n\u003cp\u003eDesign effective sequencing strategies for relapsed and refractory multiple myeloma (RRMM) and incorporate novel immunotherapies, including CAR T cells and bispecific T cell engagers.\u003c\/p\u003e\n\u003cp\u003eManage myeloma-related complications effectively, particularly bone disease, renal failure, and treatment-related infections.\u003c\/p\u003e\n\u003cp\u003eFormulate treatment plans for challenging clinical scenarios, such as extramedullary disease, plasma cell leukemia, patient frailty, and relapse after T cell-redirected therapies.\u003c\/p\u003e\n\u003cp\u003eAddress and manage other plasma cell disorders, specifically Waldenström’s Macroglobulinemia and AL Amyloidosis.\u003c\/p\u003e\n\u003cp\u003eTarget Audience\u003c\/p\u003e\n\u003cp\u003eThe IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.\u003c\/p\u003e\n\u003cp\u003eBest for hematologists, medical oncologists, nephrologists, and infectious disease specialists.\u003c\/p\u003e\n\u003cp\u003eTopics\u003c\/p\u003e\n\u003cp\u003eMultiple Myeloma: A Cure is on the Horizon\u003c\/p\u003e\n\u003cp\u003eDiagnostic Testing for Multiple Myeloma, Risk Stratification and Follow-up\u003c\/p\u003e\n\u003cp\u003eUpdate and Recommendations on Imaging Techniques in Myeloma\u003c\/p\u003e\n\u003cp\u003eMRD Testing in Multiple Myeloma\u003c\/p\u003e\n\u003cp\u003eNew Risk Stratification in Multiple Myeloma\u003c\/p\u003e\n\u003cp\u003eLive Panel Discussion: Diagnosis and Follow Up of Patients\u003c\/p\u003e\n\u003cp\u003eManagement of Clinical Significance\/Smoldering Myeloma\u003c\/p\u003e\n\u003cp\u003eManagement of Newly Diagnosed MM Transplant Eligible\u003c\/p\u003e\n\u003cp\u003eManagement of Newly Diagnosed MM Non-Transplant Eligible\u003c\/p\u003e\n\u003cp\u003eLive Panel Discussion: How to Manage SMM and NDMM\u003c\/p\u003e\n\u003cp\u003eThe Future of Multiple Myeloma\u003c\/p\u003e\n\u003cp\u003eOptimal Sequencing for RRMM Patients in Their 1st and 2nd Relapse\u003c\/p\u003e\n\u003cp\u003eNovel Treatments for MM Besides Cell Therapies and Bispecifics\u003c\/p\u003e\n\u003cp\u003eLive Panel Discussion: Sequencing of Therapies in RRMM\u003c\/p\u003e\n\u003cp\u003eCAR T Cells\u003c\/p\u003e\n\u003cp\u003eBispecific T Cell Engagers\u003c\/p\u003e\n\u003cp\u003eBone Disease and Renal Failure\u003c\/p\u003e\n\u003cp\u003eInfection and Vaccinations\u003c\/p\u003e\n\u003cp\u003eLive Panel Discussion: Managing Myeloma Related Complications\u003c\/p\u003e\n\u003cp\u003eWaldenström’s Macroglobulinemia\u003c\/p\u003e\n\u003cp\u003eAL Amyloidosis\u003c\/p\u003e\n\u003cp\u003eLive Panel Discussion: Managing Other Dysproteinemias\u003c\/p\u003e\n\u003cp\u003eRelapse After T Cell Redirected Therapies\u003c\/p\u003e\n\u003cp\u003eExtramedullary Disease and Plasma Cell Leukemia\u003c\/p\u003e\n\u003cp\u003eLive Panel Discussion: Challenging Questions in MM\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405822546116,"sku":null,"price":129.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/International-Myeloma-Society-Educational-Workshop-2025.jpg?v=1784216679","url":"https:\/\/medicalcoursespro.com\/products\/international-myeloma-society-educational-workshop-2025","provider":"Medicalcoursespro","version":"1.0","type":"link"}